Sanofi, JHL Biotech Launch Biologics Alliance in China

With FDA's clearance, Kedrion can manufacture Ryplazim (plasminogen, human-tvmh), the first and only FDA-approved therapy for treating PLGD-1, at its Bolognana, Italy, site.

The investment will allow Sanofi to strengthen antibody bioproduction at its Lyon Gerland site in France.

Under the collaboration, the companies will create and test circVec DNA–LNP formulations with an eye toward potential therapeutic applications.

Eisai Europe and Biogen have received a positive opinion for the monoclonal antibody therapy to be used as a treatment of adult patients with early Alzheimer’s disease.

Ginkgo Bioworks has achieved the first milestone in an ongoing partnership with Merck, known as MSD outside of the United States and Canada, aimed at improving biologics production.

Under an agreement, Leads Biolabs has granted the new company, Oblenio Bio, an exclusive option to license LBL-051, a tri-specific T-cell engager antibody.